ZA977541B - Recombinant toxin fragments. - Google Patents
Recombinant toxin fragments.Info
- Publication number
- ZA977541B ZA977541B ZA9707541A ZA977541A ZA977541B ZA 977541 B ZA977541 B ZA 977541B ZA 9707541 A ZA9707541 A ZA 9707541A ZA 977541 A ZA977541 A ZA 977541A ZA 977541 B ZA977541 B ZA 977541B
- Authority
- ZA
- South Africa
- Prior art keywords
- polypeptide
- domain
- exocytosis
- toxin
- recombinant toxin
- Prior art date
Links
- 231100000765 toxin Toxicity 0.000 title abstract 2
- 239000003053 toxin Substances 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 12
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 12
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 12
- 210000004027 cell Anatomy 0.000 abstract 3
- 108030001720 Bontoxilysin Proteins 0.000 abstract 1
- 108010055044 Tetanus Toxin Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 229940053031 botulinum toxin Drugs 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 231100001102 clostridial toxin Toxicity 0.000 abstract 1
- 230000028023 exocytosis Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000025743 negative regulation of exocytosis Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
- 229940118376 tetanus toxin Drugs 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9617671.4A GB9617671D0 (en) | 1996-08-23 | 1996-08-23 | Recombinant toxin fragments |
GBGB9625996.5A GB9625996D0 (en) | 1996-08-23 | 1996-12-13 | Recombinant toxin fragments |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA977541B true ZA977541B (en) | 1998-05-27 |
Family
ID=26309911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9707541A ZA977541B (en) | 1996-08-23 | 1997-08-22 | Recombinant toxin fragments. |
Country Status (10)
Country | Link |
---|---|
US (7) | US6461617B1 (xx) |
EP (1) | EP0939818B1 (xx) |
AT (1) | ATE294238T1 (xx) |
AU (1) | AU723397B2 (xx) |
CA (1) | CA2264191C (xx) |
DE (1) | DE69733146T2 (xx) |
DK (1) | DK0939818T3 (xx) |
GB (2) | GB9617671D0 (xx) |
WO (1) | WO1998007864A1 (xx) |
ZA (1) | ZA977541B (xx) |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
US7037680B2 (en) * | 1993-09-21 | 2006-05-02 | The United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US20060141572A1 (en) * | 1993-09-21 | 2006-06-29 | Smith Leonard A | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US7227010B2 (en) | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US8012491B2 (en) | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
AU4641299A (en) * | 1998-07-22 | 2000-02-14 | Agricultural Research Council | Vaccine comprising a non-toxic immunogenic derivative of (clostridium botulinum)type d neurotoxin |
US8790897B2 (en) | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US20080249019A1 (en) * | 1998-08-25 | 2008-10-09 | Syntaxin, Ltd. | Treatment of mucus hypersecretion |
US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
GB9824282D0 (en) * | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
EP2267008B1 (en) | 1999-08-25 | 2014-07-02 | Allergan, Inc. | Activatable recombinant neurotoxins |
US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
AU2005227383B2 (en) * | 1999-09-23 | 2008-08-21 | Ipsen Bioinnovation Limited | Inhibition of secretion from non-neuronal cells |
US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
DK1234043T3 (da) * | 1999-12-02 | 2004-07-19 | Health Prot Agency | Konstruktion for afgivelse af terapeutiske midler til neuroceller |
US7368532B2 (en) * | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US20030219462A1 (en) * | 2000-07-21 | 2003-11-27 | Allergan Sales, Inc | Clostridial neurotoxin compositions and modified clostridial neurotoxins |
US6831059B2 (en) | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
EP1409529B1 (en) * | 2000-11-06 | 2007-08-29 | United States Army Medical Research and Material Command | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
US7223577B2 (en) | 2000-11-17 | 2007-05-29 | Allergan, Inc. | Post-translational modifications and Clostridial neurotoxins |
US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
US7115399B2 (en) * | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
US20040115727A1 (en) * | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
US7341843B2 (en) * | 2003-04-11 | 2008-03-11 | Allergan, Inc. | Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
GB0321344D0 (en) | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
WO2006001542A1 (ja) * | 2004-06-28 | 2006-01-05 | Japan Science And Technology Agency | 毒素中和性ペプチドのスクリーニング方法とstx2阻害性ペプチド並びにベロ毒素中和剤 |
US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
DE102004035606A1 (de) * | 2004-07-22 | 2006-03-30 | Biotecon Therapeutics Gmbh | Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
WO2006026780A1 (en) * | 2004-09-01 | 2006-03-09 | Allergan, Inc. | Degradable clostridial toxins |
US7179474B2 (en) | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
US7429386B2 (en) | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
CA2582552A1 (en) * | 2004-10-21 | 2006-05-04 | Igf Oncology, Llc | Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer |
EP1824971B1 (en) | 2004-11-22 | 2016-01-13 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US7659092B2 (en) | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
CA2595115C (en) * | 2004-12-01 | 2014-01-21 | Health Protection Agency | Fusion proteins for treating, preventing or ameliorating pain |
GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
CN101146554B (zh) * | 2005-01-27 | 2012-10-10 | 加州大学评议会 | 中和肉毒杆菌神经毒素的治疗性单克隆抗体 |
WO2006101809A1 (en) | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
US8021859B2 (en) * | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
US7419675B2 (en) | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
ES2396794T3 (es) * | 2005-08-18 | 2013-02-27 | Zimmer Gmbh | Artículos de polietileno de peso molecular ultra-alto y métodos para formar artículos de polietileno de peso molecular ultra-alto |
ES2369558T3 (es) * | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
DK1931379T3 (da) | 2005-10-07 | 2013-08-19 | Sec Dep For Health | Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme |
AU2011202219B2 (en) * | 2005-12-01 | 2015-05-28 | Allergan Inc. | Fusion proteins |
GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
GB0610868D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
US7855268B2 (en) * | 2006-06-01 | 2010-12-21 | Allergan, Inc. | Tolerogizing compositions comprising botulinum toxin type B peptides |
EP2041162A2 (en) | 2006-07-11 | 2009-04-01 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
JP2009543558A (ja) | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
WO2008008803A2 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
EP2134749B1 (en) | 2007-03-22 | 2013-11-06 | The Regents of the University of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US8664290B2 (en) * | 2007-04-10 | 2014-03-04 | Zimmer, Inc. | Antioxidant stabilized crosslinked ultra-high molecular weight polyethylene for medical device applications |
KR20100088683A (ko) * | 2007-10-23 | 2010-08-10 | 알러간, 인코포레이티드 | 변형 클로스트리듐 독소를 사용한 만성 신경성 염증의 치료 방법 |
CN101918021A (zh) * | 2007-10-23 | 2010-12-15 | 阿勒根公司 | 使用经修饰的梭菌毒素治疗泌尿生殖***神经疾病的方法 |
US8652212B2 (en) * | 2008-01-30 | 2014-02-18 | Zimmer, Inc. | Orthopedic component of low stiffness |
DK3031825T3 (da) | 2008-03-14 | 2019-10-28 | Allergan Inc | Immunbaserede aktivitetsassays for botulinum-toxin serotype a |
EP3473643A1 (en) | 2008-06-12 | 2019-04-24 | Ipsen Bioinnovation Limited | Fusion proteins for use in the treatemnt of cancer |
BRPI0915888E2 (pt) * | 2008-06-12 | 2020-09-01 | Syntaxin Ltd | polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso |
WO2010014854A2 (en) | 2008-07-31 | 2010-02-04 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
CA2745657C (en) | 2008-12-04 | 2022-06-21 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
CA2746425C (en) | 2008-12-10 | 2016-05-03 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
EP2568285B1 (en) | 2009-03-13 | 2019-12-25 | Allergan, Inc. | Immuno-based retargeted endopeptidase activity assays |
EP2512505A2 (en) | 2009-12-16 | 2012-10-24 | Allergan, Inc. | Modified clostridial toxins comprising an integrated protease cleavage site-binding domain |
WO2011091419A2 (en) | 2010-01-25 | 2011-07-28 | New York Universiy | Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery |
EP2684890B1 (en) | 2010-01-25 | 2016-04-20 | Allergan, Inc. | Methods of intracellular conversion of single-chain proteins into their di-chain form |
CN103228286B (zh) | 2010-05-20 | 2018-01-02 | 阿勒根公司 | 可降解梭菌毒素 |
WO2012047427A2 (en) | 2010-08-31 | 2012-04-12 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
WO2012048246A1 (en) | 2010-10-08 | 2012-04-12 | Allergan, Inc. | Reduction of antibody response against botulinum neurotoxin and variants thereof |
WO2012109387A1 (en) | 2011-02-08 | 2012-08-16 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
CN108178801B (zh) | 2012-05-30 | 2022-05-03 | 哈佛大学校长及研究员协会 | 工程化的肉毒神经毒素 |
US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
GB201219024D0 (en) | 2012-10-23 | 2012-12-05 | Syntaxin Ltd | Assay |
CN104870468B (zh) * | 2012-11-21 | 2020-11-10 | 益普生生物创新有限公司 | 用于制备经蛋白水解处理的多肽的方法 |
JP2016513082A (ja) | 2013-01-28 | 2016-05-12 | ニューヨーク・ユニバーシティ | 無毒性神経毒誘導体を用いる治療方法 |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
WO2016094555A1 (en) * | 2014-12-09 | 2016-06-16 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
EP3822286A1 (en) | 2015-01-09 | 2021-05-19 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
WO2016154534A1 (en) | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
US11117935B2 (en) | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
KR102444230B1 (ko) | 2016-09-13 | 2022-09-19 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
JP7118055B2 (ja) | 2016-09-29 | 2022-08-15 | イプセン バイオファーム リミテッド | ハイブリッド神経毒 |
EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
US11306347B2 (en) | 2016-10-20 | 2022-04-19 | President And Fellows Of Harvard College | In vitro and cell based assays for measuring the activity of botulinum neurotoxins |
EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
WO2019145577A1 (en) | 2018-01-29 | 2019-08-01 | Ipsen Biopharm Limited | Non-neuronal snare-cleaving botulinum neurotoxins |
WO2019162696A1 (en) | 2018-02-26 | 2019-08-29 | Ipsen Biopharm Limited | Use of ultrasound to guide injection of non-cytotoxic protease |
EP3796929A1 (en) | 2018-05-21 | 2021-03-31 | Ipsen Biopharm Limited | Suppression of bone cancer-induced allodynia |
GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
EP3660509B1 (en) | 2018-11-29 | 2022-03-09 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
GB201900621D0 (en) | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
GB201914034D0 (en) | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
US20230190657A1 (en) | 2020-05-22 | 2023-06-22 | Trustees Of Boston University | Methods and compositions for treating a fibrotic disease |
WO2021247475A1 (en) * | 2020-06-02 | 2021-12-09 | Trustees Of Boston University | Production of soluble relaxin and relaxin analogs |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
GB202104294D0 (en) | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
WO2022208091A1 (en) | 2021-03-30 | 2022-10-06 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
BR112023018473A2 (pt) | 2021-03-30 | 2023-11-14 | Ipsen Biopharm Ltd | Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
WO2023105289A1 (en) | 2021-12-06 | 2023-06-15 | Dublin City University | Methods and compositions for the treatment of pain |
GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4594336A (en) * | 1982-09-28 | 1986-06-10 | Institut Pasteur | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application |
US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5919665A (en) | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
JPH05502880A (ja) | 1989-12-22 | 1993-05-20 | セラジェン・インコーポレーテッド | トランスロケーション領域および細胞結合領域を有するハイブリッド分子 |
WO1992015327A1 (en) | 1991-03-08 | 1992-09-17 | Protein Design Labs, Inc. | Recombinant double chain immunotoxins |
WO1993004191A1 (en) | 1991-08-15 | 1993-03-04 | Neorx Corporation | Noncytolytic toxin conjugates |
AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
GB9305919D0 (en) | 1993-03-22 | 1993-05-12 | Health Lab Service Board | Botulinum toxin polypeptides and their use as vaccines |
US7214787B1 (en) | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
US5962637A (en) | 1994-06-03 | 1999-10-05 | Microbiological Research Authority | Toxin assay |
CA2203504A1 (en) * | 1994-10-24 | 1996-05-02 | James A. Williams | Vaccine and antitoxin for treatment and prevention of c. difficile disease |
US6967088B1 (en) | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
CA2216425C (en) | 1996-03-23 | 2003-08-12 | The Research Foundation For Microbial Diseases Of Osaka University | Tetanus toxin functional fragment antigen and tetanus vaccine |
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US8012491B2 (en) * | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
CA2296765A1 (en) | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | Soluble recombinant botulinum toxin proteins |
US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US6822076B2 (en) | 1998-05-13 | 2004-11-23 | Biotecon Therapeutics Gmbh | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US20080249019A1 (en) | 1998-08-25 | 2008-10-09 | Syntaxin, Ltd. | Treatment of mucus hypersecretion |
US8790897B2 (en) | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
GB9824282D0 (en) | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
GB9914861D0 (en) | 1999-06-25 | 1999-08-25 | Imperial College | Tetanus toxin polypeptides |
US6535580B1 (en) | 1999-07-27 | 2003-03-18 | Agere Systems Inc. | Signature device for home phoneline network devices |
US7740868B2 (en) * | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
EP2267008B1 (en) * | 1999-08-25 | 2014-07-02 | Allergan, Inc. | Activatable recombinant neurotoxins |
GB9921592D0 (en) * | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
US20030180289A1 (en) | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
GB9922554D0 (en) * | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
DK1234043T3 (da) * | 1999-12-02 | 2004-07-19 | Health Prot Agency | Konstruktion for afgivelse af terapeutiske midler til neuroceller |
US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
US6787517B1 (en) | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
GB0112687D0 (en) | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
JP2005538954A (ja) * | 2002-05-31 | 2005-12-22 | トーマス・ジェファーソン・ユニバーシティ | 分子の経上皮輸送用組成物及び方法 |
GB0216865D0 (en) | 2002-07-19 | 2002-08-28 | Microbiological Res Authority | Targetted agents for nerve regeneration |
WO2004052277A2 (en) * | 2002-12-05 | 2004-06-24 | Wisconsin Alumni Research Foundation | Anthrax antitoxins |
US7341843B2 (en) * | 2003-04-11 | 2008-03-11 | Allergan, Inc. | Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
GB0311961D0 (en) | 2003-05-23 | 2003-06-25 | Health Prot Agency | Mass-based toxin assay and substrates therefor |
GB0321344D0 (en) | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
WO2006026780A1 (en) * | 2004-09-01 | 2006-03-09 | Allergan, Inc. | Degradable clostridial toxins |
EP1824971B1 (en) | 2004-11-22 | 2016-01-13 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
AU2005311098B2 (en) * | 2004-12-01 | 2011-08-11 | Allergan, Inc. | Non-cytotoxic protein conjugates |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US7659092B2 (en) | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
CA2595115C (en) * | 2004-12-01 | 2014-01-21 | Health Protection Agency | Fusion proteins for treating, preventing or ameliorating pain |
EP1833510A4 (en) * | 2004-12-27 | 2010-02-10 | Progenics Pharmaceuticals Neva | ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME |
WO2006101809A1 (en) * | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
US7998749B2 (en) * | 2005-10-12 | 2011-08-16 | Allergan, Inc. | Assays of molecular or subcellular interactivity using depolarization after resonance transfer energy (DARET) |
EP1834962A1 (de) * | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
GB0610868D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
WO2008008803A2 (en) * | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
JP2009543558A (ja) * | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
GB0815264D0 (en) * | 2008-08-21 | 2008-09-24 | Syntaxin Ltd | Non-cytotoxic proteins |
WO2010033913A1 (en) * | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
KR20120107926A (ko) * | 2009-08-14 | 2012-10-04 | 알러간, 인코포레이티드 | 오피오이드 재표적화된 엔드펩티다아제를 사용하여 암을 치료하는 방법 |
WO2011091419A2 (en) * | 2010-01-25 | 2011-07-28 | New York Universiy | Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery |
-
1996
- 1996-08-23 GB GBGB9617671.4A patent/GB9617671D0/en active Pending
- 1996-12-13 GB GBGB9625996.5A patent/GB9625996D0/en active Pending
-
1997
- 1997-08-22 ZA ZA9707541A patent/ZA977541B/xx unknown
- 1997-08-22 CA CA2264191A patent/CA2264191C/en not_active Expired - Fee Related
- 1997-08-22 DK DK97942094T patent/DK0939818T3/da active
- 1997-08-22 EP EP97942094A patent/EP0939818B1/en not_active Expired - Lifetime
- 1997-08-22 AU AU43895/97A patent/AU723397B2/en not_active Ceased
- 1997-08-22 DE DE69733146T patent/DE69733146T2/de not_active Expired - Lifetime
- 1997-08-22 AT AT97942094T patent/ATE294238T1/de active
- 1997-08-22 WO PCT/GB1997/002273 patent/WO1998007864A1/en active IP Right Grant
-
1999
- 1999-02-23 US US09/255,829 patent/US6461617B1/en not_active Expired - Lifetime
-
2005
- 2005-03-11 US US11/077,550 patent/US7674470B2/en not_active Expired - Fee Related
-
2006
- 2006-12-22 US US11/644,010 patent/US20070248626A1/en not_active Abandoned
-
2007
- 2007-03-14 US US11/717,713 patent/US7897158B2/en not_active Expired - Fee Related
-
2008
- 2008-07-17 US US12/174,896 patent/US8454976B2/en not_active Expired - Fee Related
-
2009
- 2009-01-27 US US12/360,470 patent/US8017134B2/en not_active Expired - Fee Related
- 2009-03-06 US US12/399,542 patent/US8012479B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20070248626A1 (en) | 2007-10-25 |
US20090274708A1 (en) | 2009-11-05 |
AU723397B2 (en) | 2000-08-24 |
JP2001502890A (ja) | 2001-03-06 |
EP0939818B1 (en) | 2005-04-27 |
AU4389597A (en) | 1998-03-06 |
US7897158B2 (en) | 2011-03-01 |
US8454976B2 (en) | 2013-06-04 |
CA2264191A1 (en) | 1998-02-26 |
US20070184070A1 (en) | 2007-08-09 |
DE69733146T2 (de) | 2006-03-09 |
ATE294238T1 (de) | 2005-05-15 |
US20020044950A1 (en) | 2002-04-18 |
DK0939818T3 (da) | 2005-08-29 |
US8017134B2 (en) | 2011-09-13 |
GB9625996D0 (en) | 1997-01-29 |
EP0939818A1 (en) | 1999-09-08 |
US8012479B2 (en) | 2011-09-06 |
US20090148888A1 (en) | 2009-06-11 |
US7674470B2 (en) | 2010-03-09 |
US20090246827A1 (en) | 2009-10-01 |
CA2264191C (en) | 2012-01-17 |
JP4273250B2 (ja) | 2009-06-03 |
US20050244435A1 (en) | 2005-11-03 |
GB9617671D0 (en) | 1996-10-02 |
US6461617B1 (en) | 2002-10-08 |
WO1998007864A1 (en) | 1998-02-26 |
DE69733146D1 (de) | 2005-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9625996D0 (en) | Recombinant toxin fragments | |
WO2004024909A3 (en) | Recombinant colstridium neurotoxin fragments | |
GB2007676A (en) | Method and means for microbial polypeptide expression | |
ATE270337T1 (de) | Materialen und methoden im zusammenhang mit bindung und präsentation von substanzen auf zelloberflächen | |
GB9108652D0 (en) | Immunoreactive compounds | |
ATE25197T1 (de) | Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung. | |
BR9911549A (pt) | Processo de produção de fitase em levedura | |
IL110829A0 (en) | Hybrid toxin fragments and toxins comprising them | |
WO1993021331A3 (en) | Polysaccharide binding fusion proteins and conjugates | |
DE69532968T2 (de) | Verfahren zur sekretion thrombopoitin polypeptide | |
AU1873199A (en) | Method of identifying binding site domains that retain the capacity of binding to an epitope | |
DK1222298T3 (da) | Vektorer og fremgangsmåder til rekombinant proteinekspression | |
SE9101433D0 (sv) | Recombinant dna sequence and its use | |
CY1106110T1 (el) | ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΕΝΟΣ ΠΕΠΤΙΔΙΟΥ ΜΕ pI ΠΑΝΩ ΑΠΟ 8 Ή ΚΑΤΩ ΑΠΟ 5 | |
PT1025245E (pt) | Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes | |
ATE294856T1 (de) | Lunasin peptide | |
WO1997012044A3 (en) | Pichia secretory leader for protein expression | |
AU1503697A (en) | Method for cleaving chimeric protein using processing enzyme | |
HUT57268A (en) | Process for producing strange protheine in streptomycetes | |
DE69634757D1 (de) | Vektor zur expression von n-terminal verlängerten proteinen in hefezellen | |
WO1995013386A3 (en) | Tyrosinase-activator protein fusion enzyme | |
AR016208A1 (es) | Fragmento aislado de acidos nucleicos que codifica toda o una porcion substancial de una proteina de transporte de sacarosa, gen quimerico, celula huespedtransformada, polipeptido de dicha proteina, metodo para alterar el nivel de expresion de dicha proteina en una celula huesped, metodo para obtene | |
AU2235401A (en) | Bacillus thuringiensis hybrid toxins | |
GB9626589D0 (en) | Peptides | |
DE3873273D1 (de) | Verfahren zur selektiven spaltung von fusionsproteinen. |